Provectus Biopharmaceuticals, Inc.
PVCT
$0.0749
-$0.0042-5.31%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1,848.25% | -86.96% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1,848.25% | -86.96% | |||
| Cost of Revenue | -30.55% | 35.22% | |||
| Gross Profit | 80.90% | -80.62% | |||
| SG&A Expenses | -49.63% | 277.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -45.06% | 164.01% | |||
| Operating Income | 56.98% | -200.42% | |||
| Income Before Tax | 51.54% | -136.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 51.54% | -136.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 52.43% | -136.29% | |||
| EBIT | 56.98% | -200.42% | |||
| EBITDA | 56.99% | -201.25% | |||
| EPS Basic | 52.63% | -137.50% | |||
| Normalized Basic EPS | 57.14% | -191.67% | |||
| EPS Diluted | 52.63% | -137.50% | |||
| Normalized Diluted EPS | 57.14% | -191.67% | |||
| Average Basic Shares Outstanding | 0.00% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||